buformin has been researched along with Hypertrophy in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandrov, VA | 1 |
| Anisimov, VN | 1 |
| Belous, NM | 1 |
| Vasilyeva, IA | 1 |
| Mazon, VB | 1 |
1 other study available for buformin and Hypertrophy
| Article | Year |
|---|---|
The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats.
Topics: Animals; Buformin; Cholesterol; Dietary Carbohydrates; Diethylstilbestrol; Energy Metabolism; Female | 1980 |